Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Non-alcoholic Fatty Liver Disease

In brief

This study aims to assess the safety and tolerability of AMG 609 when administered subcutaneously as single doses in participants with non-alcoholic fatty liver disease (NAFLD).

Key facts

Study ID

NCT04857606

Run by

Amgen

People needed

47

Starts

2021-05-24

Expected to finish

2023-07-19

Last updated by the study team

2023-11-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• The Institute for Liver Health - Arizona Liver Health — Chandler, Arizona, United States
• ProSciento Incorporated — Chula Vista, California, United States
• Catalina Research Institute — Montclair, California, United States
• Inland Empire Liver Foundation — Rialto, California, United States
• Orange County Research Center — Tustin, California, United States
• Translational Clinical Research LLC — Aventura, Florida, United States
• Texas Liver Institute — San Antonio, Texas, United States
• Endeavor Clinical Trials — San Antonio, Texas, United States
• Pinnacle Clinical Research — San Antonio, Texas, United States
• McGuire VA Medical Center — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.